The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study

Maryam Babaei, MSc; Zahra Kanannejad, PhD; Najmeh Sepahi, MSc; Soheila Alyasin, MD

Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence: Soheila Alyasin, MD; Allergy Research Center, Mohammad Rasool Allah Research Tower, Khalili St., P.O. Box: 71933-5899, Shiraz, Iran
Tel: +98 71 36122268
Fax: +98 71 36281563
Email: alyasins@sums.ac.ir

Received: 21 September 2021
Revised: 12 December 2021
Accepted: 25 December 2021

Abstract
Both adaptive and innate immune responses are essential for an effective defense against the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection. We aimed to investigate the effect of the coronavirus disease 2019 (COVID-19) pandemic on patients with primary immunodeficiency (PID). This study was performed on patients who were diagnosed with PID by immunologist specialists and referred to Imam Reza Clinic of Asthma and Allergy, affiliated with Shiraz University of Medical Sciences, (Shiraz, Iran) for regular check-ups. The patients were enrolled in this cohort study and followed for any sign of COVID-19 from March 2020 to May 2021. COVID-19 infection was confirmed using a real-time polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs. Among the 90 PID patients under study, nine patients (10%) were diagnosed positive for COVID-19 infection. Five out of these nine patients belonged to the combined immunodeficiency (CID) category, while four patients were categorized as having primary antibody deficiencies (PADs). Eight patients with COVID-19 were required to be admitted to the hospital, and three patients died after hospitalization due to COVID-19 infection. It seems that patients with CID are at a higher risk of mortality, due to COVID-19 infection, that other types of PID.

Keywords ● COVID-19 ● Mortality ● Primary immunodeficiency diseases

What's Known
• As appropriate innate and adaptive immune responses are essential for SARS-CoV-2 eradication, some epidemiological studies have investigated the relationship between primary immunodeficiency diseases and the fatal risk of COVID-19.
• Recent studies suggest that patients with primary immunodeficiency in antiviral innate immune signaling or combined immunodeficiency may be predisposed to the severe form of COVID-19 infection.

What's New
• Individuals with combined immunodeficiency are more susceptible to the severe form of COVID-19 infection than patients with other types of primary immunological deficiencies.
• Some primary immunodeficiency patients require more attention due to their age, category, and additional comorbidities.

Introduction
Currently, the world has encountered the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus can induce respiratory tract infection accompanied by cold, sneezes, pneumonia, and coughs. Some conditions, such as obesity, old age, hypertension, male gender, cancer, diabetes, chronic lung disease, and heart conditions are considered as risk factors predisposing individuals to a severe form of the disease. An orchestrated adaptive and innate immune responses is essential for an effective defense against SARS-CoV-2 infection without the negative side effects of a hyper-immune response. In this regard, it is expected that patients with primary immunodeficiency (PID) may be more susceptible to developing the severe form of COVID-19. Some studies have investigated...
COVID-19 and primary immunodeficiency

It seems that PID patients with deficiency in antiviral innate immune signaling or combined immunodeficiency (CID) may be linked to the severe form of COVID-19 infection. In this study, we aimed to investigate the rate and outcomes of COVID-19 infection among the cases diagnosed with PID.

Patients and Methods

This study was conducted on patients with PID living in Fars province and some neighboring provinces, who were referred to Imam Reza Clinic of Asthma and Allergy, affiliated with Shiraz University of Medical Sciences, (Shiraz, Iran). The diagnosis and management of PID patients were performed by immunologist specialists in this clinic according to the criteria of the European Society for Immunodeficiencies (ESID). All patients were followed from March 2020 to May 2021 for any sign of COVID-19, including fever, dry coughs, dyspnea, and gastrointestinal (GI) symptoms. The COVID-19 test was performed on patients with the clinical triad of coughs, fever, and dyspnea using a real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs. Informed consents were obtained from all the participants. This study was approved by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1399.845). The data were analyzed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, Illinois, USA, V. 21.00).

Results

The age of the 90 PID patients who were included in the study, ranged from 4.4 months to 48 years, with a mean age of 147.9±106.5 months. This study included 36 (40%) female and 54 (60%) male patients. During the follow-up period, fever, dry coughs, dyspnea, and GI symptoms were recorded for 16.6, 8.8, 6.6, and 5.5 percent of the total patients, respectively. A positive RT-PCR test for SARS-CoV-2 was verified in nine PID patients (10%), and all cases had a history of exposure to another COVID-19-infected family member. The demographic parameters and clinical state of these patients prior to COVID-19 infection are summarized in table 1. Six out of nine PID patients (66.6%) with COVID-19 infection fully recovered, while three patients (33.3%) died from the disease. All patients had symptoms of COVID-19 infection, such as fever, coughing, respiratory distress, and dyspnea. In certain cases, GI symptoms, myalgia, and anosmia were observed. One case (P5) experienced allergic symptoms, such as a runny nose and sneezing. Eight patients showed the severe form of the disease and were required to be hospitalized. Intravenous immune globulin (IVIG) and anti-viral therapy were used for all patients during the infection. The clinical data after COVID-19 infection and the outcomes of the treatment strategy of PID patients are presented in table 2.

Discussion

In this study, nine patients were tested positive for COVID-19. The demographic and clinical data of these patients are presented in table 1. The patients were treated with IVIG and anti-viral therapy, and some were also treated with corticosteroids. The outcomes of the treatment strategy are presented in table 2.

Table 1: Demographic and clinical data of patients with primary immunodeficiency before COVID-19 infection

| ID | Age (month) | Sex | PID diagnosis | Medical problems | IVIG-RT | Other treatment |
|----|--------------|-----|---------------|------------------|---------|----------------|
| P1 | 5            | F   | SCID          | HM, DCM, VSD, OM, BCGitis, Convulsion, Rash and scaring | Yes     | Prednisone     |
| P2 | 32           | F   | CID-STIM1 deficiency | AIHA, ITP, Viscosities, Nephritic syndrome, Myopathy | Yes     | Acyclovir, Co-trimoxazole, Isoniazid, Rifampin, Prednisone, Levetiracetam, Fluconazole |
| P3 | 18           | M   | ICF syndrome | SM, Cirrhosis | Yes     | Levetiracetam, Ursobil |
| P4 | 124          | F   | Ataxia-telangiectasia | None | No | None |
| P5 | 22           | M   | Bruton agammaglobulinemia | DDH, Poliomyelitis | Yes     | None |
| P6 | 27           | M   | Bruton agammaglobulinemia | Bronchiectasis | Yes     | None |
| P7 | 72           | F   | CVID          | Anemia, SMG, | No | Cefixime, Coamoxyclavle, Levofoxacin |
| P8 | 480          | F   | CVID          | SM, OM, Pneumonitis | Yes | Acyclovir, Vancomycin, Meropenem, Cromolyn |
| P9 | 204          | F   | Hyper IgE     | Dermatitis, Pneumonitis, Arthritis | Yes | Acyclovir, Vancomycin, Meropenem, Cromolyn |

PID: Primary immunodeficiency; CID: Combined immunodeficiency; SCID: Severe combined immunodeficiency; ICF: Facial anomalies syndrome; CVID: Common variable immunodeficiency; HM: Hepatomegaly; DCM: Dilated Cardiomyopathy; VSD: ventricular Septal Defect; AIHA: Autoimmune hemolytic anemia; ITP: Immune thrombocytopenic purpura; SM: Systemic mastocytosis; DDH: Developmental dysplasia of the hip; SMG: Splenomegaly; OM: Otitis media; CID-STIM1: Combined immunodeficiency due to STIM1 deficiency; P: Patient; M: Male; F: Female
for COVID-19 infection, and the mortality rate was 33.3% among these patients. All COVID-19 cases belonged to the categories of CID and primary antibody deficiencies (PAD), with a higher fatality rate among patients with CID. Similarly, in a study performed by Delavari and colleagues, CID was the main PID entity among COVID-19-positive cases, followed by humoral immunodeficiencies.6 In this context, several recent studies have found that lymphopenia with prominent decreased T cell counts (especially CD8+ cells) is associated with the severe course of COVID-19 infection. Guan Chen and colleagues reported decreased CD4+ and CD8+ T cell counts, as well as interferon gamma (IFN-γ) production by CD4+ T cells, in severe cases of COVID-19 infection.10 Another study performed by Fan Wang and colleagues showed that total lymphocytes, CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells decreased in COVID-19 patients, and severe cases had lower levels than mild ones. They also indicated a significant association between these cells and inflammatory status in COVID-19, especially for CD8+ T cells and the CD4+/CD8+ ratio.11 Reduced T cell counts (CD4+ T cells, CD8+ T cells) associated with increased serum levels of interleukin IL-6, IL-10, tumor necrosis factor (TNF)-α concentration, and T cell exhaustion were seen in COVID-19 patients requiring intensive care unit (ICU) admission.12 On the other hand, a multinational cohort study on 94 PID patients with COVID-19 infection revealed that older patients with CID manifested a milder course of COVID-19 infection than those of our study.13 Primary antibody deficiencies were identified as another dominant PID category with four COVID-19 cases, all of whom recovered after hospitalization. According to Quinti and colleagues, patients with agammaglobulinemia showed a milder course of the disease than the patients with common variable immunodeficiency (CVID) who were characterized by dysfunctional B cells.14 As B cells are considered to be one of the main sources of IL-6 production, which enhances the level of inflammatory responses, the lack of B cells in agammaglobulinemia might be considered as an advantage, since they help avoiding the development of inflammatory responses and cytokine storms.5 However, in our study, the clinical course of the disease resembled that of CVID and agammaglobulinemia

Table 2: Clinical data after COVID-19 infection and outcome of treatment strategy in 9 patients with primary immunodeficiency

| ID | Age (month) | Sex | PID diagnosis | COVID-19 related symptoms | Treatment strategy | Medication | Outcome/Cause of death |
|----|-------------|-----|---------------|---------------------------|--------------------|------------|------------------------|
| P1 | 5           | F   | SCID          | Fever, Cough, Dyspnea, Respiratory distress | Hospitalized | IVIG, Acyclovir, Clindamycin, Meropenem, Fluconazole, Steroid | Death/ARDS |
| P2 | 32          | F   | CID-STIM1 deficiency | Fever, Cough, Dyspnea, Respiratory distress, retraction, hypotension, tachypnea | Hospitalized / ICU | IVIG, Vancomycin, Meropenem, Piperacillin/ tazobactam, steroid | Death/Sepsis, Cardiorespiratory arrest |
| P3 | 18          | M   | ICF syndrome  | Fever | Hospitalized/ ICU | IVIG, Acyclovir, Vancomycin, Piperacillin/ tazobactam, steroid | Recovery |
| P4 | 124         | F   | Ataxia-telangiectasia | - | Hospitalized | IVIG | Recovery |
| P5 | 22          | M   | Bruton agammaglobulinemia | Fever, Cough, Runny nose and sneezing, myalgia | Hospitalized | IVIG, Acyclovir, Vancomycin, Piperacillin/ tazobactam, steroid | Recovery |
| P6 | 27          | M   | Bruton agammaglobulinemia | Fever, Cough, Myalgia, Anosmia | No | IVIG, Azithromycin | Recovery |
| P7 | 72          | F   | CVID          | Fever, Cough, Dyspnea, GI symptom | Hospitalized | IVIG | Recovery |
| P8 | 480         | F   | CVID          | Fever, Respiratory distress, GI symptom, Anosmia | Hospitalized | IVIG, Meropenem, Tocilizumab, Steroid, Ceftriaxone | Recovery |
| P9 | 204         | F   | Hyper IgE     | Fever, Respiratory distress | Hospitalized, ICU | IVIG, Cefixime, Cetirizine | Death/ARDS |

PID: Primary immunodeficiency; CID: Combined immunodeficiency; SCID: Severe combined immunodeficiency; ICF: Facial anomalies syndrome; CVID: Common variable immunodeficiency; IVIG: Intravenous immunoglobulin; ARDS: Acute respiratory distress syndrome; P: Patient; M: Male; F: Female
categories. These observations, along with other reports, either show that T cell response is more important against the virus or emphasize the role of B cells in the inflammation caused by SARS-CoV-2. Two out of the three PID patients died from COVID-19 infection, were under the age of three. In contrast with the results that show the mild form of the disease in children and adolescents to be due to the low expression of angiotensin-converting enzyme-2 (ACE-2) receptor and functional adaptive immunity, a fraction of them with PID who suffer from other comorbidities, may develop the severe course of the disease requiring hospital admission and even suffer a fatal outcome. In this regard, more caution should be exercised for complicated PID patients during the COVID-19 pandemic, and this should be taken into account by all physicians.

**Conclusion**

In conclusion, it seems that patients with CID are at a higher risk of mortality, due to COVID-19 infection, than other types of PID. More attention should be paid to some PID patients regarding their age, the PID categories, especially CID, and further comorbidities. Future studies may confirm the individual risk of different PID diseases, and clarify the potential need for preventative measures for specific subsets of PID patients, who are at a high risk for a critical course of COVID19.

**Acknowledgment**

This study was supported by Shiraz University of Medical Sciences (grant number: 20857). The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, as well as the Center for Development of Clinical Research of Namazi Hospital and Dr. Nasrin Shokrpour for their editorial assistance.

**Authors’ Contribution**

M.B: Conceptualization, Methodology, Formal analysis and investigation, original draft preparation, Supervision; Z.K: Formal analysis and investigation, original draft preparation, revise and editing; N.S: Formal analysis and investigation, original draft preparation; S.A: Conceptualization, revise and editing, funding acquisition, Resources, Supervision; All authors have read and approved the final manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Conflict of Interest:** None declared.

**References**

1. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020;14:407-12. doi: 10.1016/j.dsx.2020.04.020. PubMed PMID: 32335367; PubMed Central PMCID: PMCPMC7165108.

2. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus. 2020;12:e7355. doi: 10.7759/cureus.7355. PubMed PMID: 32328367; PubMed Central PMCID: PMCPMC7170025.

3. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13:1833-9. doi: 10.1016/j.jiph.2020.07.014. PubMed PMID: 32788073; PubMed Central PMCID: PMCPMC7402107.

4. Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: A review. J Infect Public Health. 2020;13:1619-29. doi: 10.1016/j.jiph.2020.07.001. PubMed PMID: 32718895; PubMed Central PMCID: PMCPMC7359800.

5. Babaha F, Rezaei N. Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor? Am J Med Sci. 2020;360:740-1. doi: 10.1016/j.amjms.2020.07.027. PubMed PMID: 32773108; PubMed Central PMCID: PMCPMC7388814.

6. Delavari S, Abolhassani H, Abolnezhadian F, Babaha F, Iranparast S, Aghanian H, et al. Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. J Clin Immunol. 2021;41:345-55. doi: 10.1007/s10875-020-00928-x. PubMed PMID: 33263173; PubMed Central PMCID: PMCPMC7707812.

7. Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, et al. Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. Front Immunol. 2020;11:614086. doi: 10.3389/fimmu.2020.614086. PubMed PMID: 33519822; PubMed Central PMCID: PMCPMC7840610.

8. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect. 2020;81:e93-e5. doi: 10.1016/j.jinf.2020.05.017. PubMed PMID: 32417309; PubMed Central PMCID:
PMCPMC7228685.

9 Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019;7:1763-70. doi: 10.1016/j.jaip.2019.02.004. PubMed PMID: 30776527.

10 Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620-9. doi: 10.1172/JCI137244. PubMed PMID: 32217835; PubMed Central PMCID: PMCPMC7190990.

11 Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020;221:1762-9. doi: 10.1093/infdis/jiaa150. PubMed PMID: 32227123; PubMed Central PMCID: PMCPMC7184346.

12 Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827. PubMed PMID: 32425950; PubMed Central PMCID: PMCPMC7205903.

13 Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immunol. 2021;147:520-31. doi: 10.1016/j.jaci.2020.09.010. PubMed PMID: 32980424; PubMed Central PMCID: PMCPMC7832563.

14 Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146:211-3. doi: 10.1016/j.jaci.2020.04.013. PubMed PMID: 32333914; PubMed Central PMCID: PMCPMC7175894.